Nutex Health Statistics
Total Valuation
Nutex Health has a market cap or net worth of $682.98 million. The enterprise value is $979.70 million.
| Market Cap | 682.98M |
| Enterprise Value | 979.70M |
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutex Health has 5.53 million shares outstanding. The number of shares has increased by 21.89% in one year.
| Current Share Class | 5.53M |
| Shares Outstanding | 5.53M |
| Shares Change (YoY) | +21.89% |
| Shares Change (QoQ) | +8.79% |
| Owned by Insiders (%) | 35.61% |
| Owned by Institutions (%) | 16.50% |
| Float | 3.34M |
Valuation Ratios
The trailing PE ratio is 12.72 and the forward PE ratio is 27.60.
| PE Ratio | 12.72 |
| Forward PE | 27.60 |
| PS Ratio | 1.31 |
| Forward PS | 1.73 |
| PB Ratio | 4.65 |
| P/TBV Ratio | 5.84 |
| P/FCF Ratio | 32.76 |
| P/OCF Ratio | 29.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.25, with an EV/FCF ratio of 46.99.
| EV / Earnings | 18.78 |
| EV / Sales | 2.04 |
| EV / EBITDA | 6.25 |
| EV / EBIT | 7.11 |
| EV / FCF | 46.99 |
Financial Position
The company has a current ratio of 2.08, with a Debt / Equity ratio of 1.69.
| Current Ratio | 2.08 |
| Quick Ratio | 1.99 |
| Debt / Equity | 1.69 |
| Debt / EBITDA | 2.14 |
| Debt / FCF | 16.32 |
| Interest Coverage | 6.91 |
Financial Efficiency
Return on equity (ROE) is 67.81% and return on invested capital (ROIC) is 19.19%.
| Return on Equity (ROE) | 67.81% |
| Return on Assets (ROA) | 16.34% |
| Return on Invested Capital (ROIC) | 19.19% |
| Return on Capital Employed (ROCE) | 26.77% |
| Revenue Per Employee | $599,936 |
| Profits Per Employee | $65,224 |
| Employee Count | 800 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 84.84 |
Taxes
In the past 12 months, Nutex Health has paid $14.48 million in taxes.
| Income Tax | 14.48M |
| Effective Tax Rate | 13.19% |
Stock Price Statistics
The stock price has increased by +1,744.16% in the last 52 weeks. The beta is 2.20, so Nutex Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.20 |
| 52-Week Price Change | +1,744.16% |
| 50-Day Moving Average | 75.80 |
| 200-Day Moving Average | 38.49 |
| Relative Strength Index (RSI) | 61.23 |
| Average Volume (20 Days) | 148,432 |
Short Selling Information
The latest short interest is 105,012, so 1.90% of the outstanding shares have been sold short.
| Short Interest | 105,012 |
| Short Previous Month | 84,591 |
| Short % of Shares Out | 1.90% |
| Short % of Float | 3.14% |
| Short Ratio (days to cover) | 0.95 |
Income Statement
In the last 12 months, Nutex Health had revenue of $479.95 million and earned $52.18 million in profits. Earnings per share was $9.71.
| Revenue | 479.95M |
| Gross Profit | 215.23M |
| Operating Income | 137.71M |
| Pretax Income | -39.95M |
| Net Income | 52.18M |
| EBITDA | 156.68M |
| EBIT | 137.71M |
| Earnings Per Share (EPS) | $9.71 |
Balance Sheet
The company has $43.58 million in cash and $340.30 million in debt, giving a net cash position of -$296.72 million or -$53.67 per share.
| Cash & Cash Equivalents | 43.58M |
| Total Debt | 340.30M |
| Net Cash | -296.72M |
| Net Cash Per Share | -$53.67 |
| Equity (Book Value) | 201.89M |
| Book Value Per Share | 26.55 |
| Working Capital | 151.61M |
Cash Flow
In the last 12 months, operating cash flow was $23.15 million and capital expenditures -$2.30 million, giving a free cash flow of $20.85 million.
| Operating Cash Flow | 23.15M |
| Capital Expenditures | -2.30M |
| Free Cash Flow | 20.85M |
| FCF Per Share | $3.77 |
Margins
Gross margin is 44.85%, with operating and profit margins of 28.69% and 10.87%.
| Gross Margin | 44.85% |
| Operating Margin | 28.69% |
| Pretax Margin | 22.87% |
| Profit Margin | 10.87% |
| EBITDA Margin | 32.64% |
| EBIT Margin | 28.69% |
| FCF Margin | 4.34% |
Dividends & Yields
Nutex Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.89% |
| Shareholder Yield | n/a |
| Earnings Yield | 7.64% |
| FCF Yield | 3.05% |
Analyst Forecast
The average price target for Nutex Health is $80.00, which is -35.24% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $80.00 |
| Price Target Difference | -35.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 3, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Nutex Health has an Altman Z-Score of 1.06 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.06 |
| Piotroski F-Score | 7 |